Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
ISSN
01663542
Date Issued
2019
Author(s)
DOI
10.1016/j.antiviral.2019.104543
Subjects